Effect of supplementation in treatment of women with cervical intraepithelial neoplasia 2 and 3
Phase 3
- Conditions
- C53.9Cervical intraepithelial neoplasia 2 and 3.Cervix uteri, unspecified
- Registration Number
- IRCT201601045623N65
- Lead Sponsor
- Vice chancellor for research, Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 58
Inclusion Criteria
Women with cervical intraepithelial neoplasia 2 and 3
Aged 25 to 65 years old
Exclusion Criteria
Women who had a history of cervical cancer or other cancers of the lower genital tract
History of hysterectomy or destructive therapy of the cervix
Pregnant women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence. Timepoint: Six months after intervention. Method of measurement: Colposcopy.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie vitamin D's effect on cervical intraepithelial neoplasia 2/3 recurrence prevention?
How does vitamin D supplementation compare to standard-of-care treatments for CIN2/3 in terms of recurrence rates and metabolic outcomes?
Which biomarkers are associated with response to vitamin D therapy in women with C53.9 cervical intraepithelial neoplasia?
What adverse events are reported with vitamin D supplementation in CIN2/3 trials and how are they managed?
Are there combination therapies involving vitamin D that show improved outcomes for CIN2/3 compared to monotherapy?